Clinical Trial Update: Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial of REGN5093-M114, a METxMET antibody-drug conjugate, in MET-overexpressing advanced cancers including non-small cell lung cancer, has been termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• REGN5093-M114 (METxMET Antibody-Drug Conjugate)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Advanced NSCLC | Phase 1 | Status: TERMINATED